Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid LeukemiaNeil P Shah
Blood|December 8, 2009
Fine-tuning targeted therapy of CMLNeil P Shah
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Progressive thoughts about progressive diseaseNeil P Shah
Oncology (Williston Park, N.Y.)|November 27, 2012
Front-line TKI therapy for chronic-phase CML: the luxury of choiceNeil P Shah
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Ponatinib: targeting the T315I mutation in chronic myelogenous leukemiaNeil P Shah
Nature Medicine|May 9, 2008
Bench to bedside: BRCA: from therapeutic target to therapeutic shieldNeil P Shah
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
Advanced CML: therapeutic options for patients in accelerated and blast phasesNeil P Shah
Hematology. American Society of Hematology. Education Program|November 24, 2005
Loss of response to imatinib: mechanisms and managementNeil P Shah
Drugs of Today (Barcelona, Spain : 1998)|February 23, 2007
DasatinibNeil P Shah
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2017
Front-Line Treatment Options for Chronic-Phase Chronic Myeloid LeukemiaNeil P Shah
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid LeukemiaNeil P Shah
Blood|December 8, 2009
Fine-tuning targeted therapy of CMLNeil P Shah
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Progressive thoughts about progressive diseaseNeil P Shah
Oncology (Williston Park, N.Y.)|November 27, 2012
Front-line TKI therapy for chronic-phase CML: the luxury of choiceNeil P Shah
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Ponatinib: targeting the T315I mutation in chronic myelogenous leukemiaNeil P Shah
Nature Medicine|May 9, 2008
Bench to bedside: BRCA: from therapeutic target to therapeutic shieldNeil P Shah
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
Advanced CML: therapeutic options for patients in accelerated and blast phasesNeil P Shah
Hematology. American Society of Hematology. Education Program|November 24, 2005
Loss of response to imatinib: mechanisms and managementNeil P Shah
Drugs of Today (Barcelona, Spain : 1998)|February 23, 2007
DasatinibNeil P Shah
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2017
Front-Line Treatment Options for Chronic-Phase Chronic Myeloid LeukemiaNeil P Shah
Pageof 12